1. HBW Insight
  2. >>Wellness
  3. >>Business

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

 
• By Eileen Francis

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Attention Please_1014394012_1200.jpg

Creekside Natural Therapeutics LLC failed to support claims that its Focused Mind Jr. supplement is an alternative to ADHD drugs for children in a review by an industry self-regulation program without enforcement authority. After failing to agree to change the advertising, the firm might get the full attention of a federal enforcement agency prioritizing false claims for children's products.

In a report published 15 January, the Council of Better Business Bureaus’ National Advertising Division said Creekside Natural didn’t submit an advertiser’s statement following the investigative arm’s review of the firm’s online ad claims as part of its monitoring of dietary

When NAD attorneys recommend changes to claims following reviews, firms making the questioned claims are required to submit statements for NAD’s reports noting they will either comply or appeal the decisions to the National Advertising Review Board, also part of the CBBB’s industry self-regulation program

More from Business

Ceres Pharma Acquires Belgian Probiotics Player Vésale

 
• By Tom Gallen

Deal adds to Ceres' portfolio probiotic supplements in categories such as women's health and immunity marketed in Europe, Asia and North America.

Time’s Up For Time-Line Mitopure Supplement Marketer’s Aging Claims In NAD Review

 
• By Malcolm Spicer

NAD says Amazentis didn’t substantiate cellular performance and muscle function claims for its supplements containing proprietary ingredient Mitropure but provided “a sufficiently reliable and reasonable basis” for “clinically proven to revitalize mitochondria.”

Haleon Utilizing AI To Develop Natural CHC Products

 
• By Tom Gallen

Haleon is partnering with San Francisco's Brightseed to utilize its AI technology to identify bioactive compounds in plants for use in consumer health products.

Haleon Targets Low Income Households In Push To Reach 1bn More Consumers

 
• By Tom Gallen

Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.

More from Wellness

Haleon Targets Low Income Households In Push To Reach 1bn More Consumers

 
• By Tom Gallen

Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.

Supplementation Unlikely To Help With Hereditary Hair Loss, Says German Agency

 
• By David Ridley

Germany’s Federal Institute for Risk Assessment says that there is "no evidence that people with androgenetic alopecia have special dietary needs or a special nutrient requirement.”

NAD Asks FTC To Pull Bandage Off Firm’s Plan To Exhaust Inventory Using ‘2X Faster Healing’ Claim

 
• By Malcolm Spicer

After National Advertising Division attorneys, in a review prompted by a challenge by Band-Aid line marketer Kenvue, recommended ASO LLV cease use of its “up to 2x faster healing” claim, they determined the firm had not fully complied.